patents

John Gapper

Whether or not Pfizer’s tactics to preserve Lipitor sales as it loses its patent protection succeed, they are a sobering reflection of the lack of success of big pharmaceutical companies in trying to replicate their past days of blockbuster glory.

Alan Rappeport’s report on how Pfizer is heavily cutting the price of its anti-cholesterol drug to see off generic competition illustrates how important blockbuster drugs from the past remain to Big Pharma.

As Forbes noted in a long piece on Lipitor, this reflects the prolonged squeeze on pharma companies, which have been struggling to come up with new products to replace those now falling off the patent cliff – Lipitor being the prime example. Read more

Andrew Hill

It’s sad to see Eastman Kodak reduced – at least in many investors’ eyes – to a punt on the photographic pioneer’s patents.

On Wednesday, its shares jumped by a quarter on the suggestion that its intellectual property could be worth more than the company itself. It’s a sign of the times as much as it is a sign of Kodak’s failure to find a convincing answer to the digital photography challenge: Google’s $12.5bn agreed bid this week for Motorola Mobility was largely based on the value of the mobile phonemaker’s patent portfolioRead more